Figure 5
From: Anti-apoptotic role and clinical relevance of neurotrophins in diffuse large B-cell lymphomas
In vivo efficacy of K252a in a DLBCL xenograft model. For the GCB-DLBCL xenograft model, SCID mice were injected with 1 × 107 SUDHL4 cells subcutaneously. (A) The human SUDHL4 cell origin of tumours was confirmed by immunohistochemistry (with anti-human CD20) and representative stainings for NGF, BDNF, Trk, and p75NTR receptor are done (× 400). (B) After the tumours had become established (∼6 weeks after tumour inoculation), mice were treated with vehicle (Controls, n=10), K252a (0.5 mg kg−1, n=10) or rituximab (25 mg kg−1, n=5) or both agents (n=8) for 3 weeks. Results are expressed as mean tumour volumes (cm3)±s.d. *, **P<0.05 and 0.01 respectively vs control group, Student’s t-test. (C) Example of a representative western blotting analysis of Ki67 expression and PARP cleavage is shown for tumour samples of K252a-treated mice compared with vehicle control mice. Actin is done as loading control. The full colour version of this figure is available at British Journal of Cancer online.
